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Ebenezer K Tetteh*† and Stephen Morris†Abstract
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing,
reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the
routine use of cost-effectiveness analyses or health technology assessments to determine which medical technologies
offer value-for-money. The manner in which these assessments are conducted suggests that, holding all else equal,
the economic value of biologic drugs may be determined by how much is spent on administering these drugs or
trade-offs between drug acquisition and administration costs. Yet, on the supply-side, it seems very little attention is
given to how manufacturing and formulation choices affect healthcare delivery costs. This paper evaluates variations in
the administration costs of biologic drugs, taking care to ensure consistent inclusion of all relevant cost resources.
From this, it develops a regression-based algorithm with which manufacturers could possibly predict, during process
development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their
products.
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The adoption and utilization of beneficial medical tech-
nologies including biologic drugs has, in recent times,
been subject to a number of regulatory, marketing, reim-
bursement (coverage) and other demand-side hurdles
including the so-called risk-sharing arrangements. These
demand-side hurdles have evolved out of increasing
healthcare payer concerns about the high acquisition costs
and budgetary impacts of these medical technologies.
Notably, healthcare payers have turned to the use of
cost-effectiveness analysis (CEA), budget impact analysis
or health technology assessments (HTA) to estimate
cost-effectiveness and affordability prior to deciding
whether to adopt or reimburse the utilization of biologics
within their original or restricted marketing authorization
or not. This typically involves comparing, over a specified
time period, total healthcare delivery costs (i.e., the sum of
drug acquisition costs plus administration and future
healthcare-related costs) associated with a given technol-
ogy and the total health benefits expected. Holding all else* Correspondence: e.tetteh@ucl.ac.uk
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reproduction in any medium, provided the origconstant, the estimated cost-effectiveness of a biologic
drug may be dictated by how much of healthcare resources
are spent on drug administration, and whether trade-offs
exist between drug acquisition and administration costs.
On the supply-side, it has been observed that biological
drug candidates are developed with a skewed focus on
clinical efficacy and safety to the neglect of issues related
to the ease of manufacturing, affordability and cost-
effectiveness of these therapies to healthcare payers. This
often leads to unnecessary waste and excessive reworking
of manufactured products, and a growing concern over
the failures and struggles manufacturers face in passing
through what is becoming an increasingly complex set of
regulatory and demand-restricting hurdles. That latter is
known to be associated with significant delays in market
launch, in addition to the time and revenue lost in price
negotiations [1]. So besides worrying about the ease of
manufacturing, it is also useful for manufacturers to, at
least, consider prior to market launch, the administration
and total healthcare delivery costs associated with the
different ways they choose to manufacture and formulate
their products. In that case, manufacturers’ evaluation of
drug administration costs should be done in the same
manner as it will be conducted by healthcare payers. Theis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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biologic drugs, to identify the factors that affect variation
in these costs, and argue why such evaluations are an
important step in biopharmaceutical manufacturing. That
is, we explore why pharmaceutical manufacturers should
consider the link between administration costs (and how
this is influenced by formulation and manufacturing), total
healthcare delivery costs and value-for-money when mak-
ing their go-no-go R&D decisions.
Our study objectives and design are motivated by two
key points. First, in a systematic review of the economic
value of reducing medication dosing frequency using
drug delivery systems, Cheng et al. [2] found that, in
most cases, drug products with less-frequent dosing
schedules tend to be cost effective when compared to
conventional (standard) formulations containing the same
active moiety – although these ‘advanced’ or ‘improved’
delivery systems may be expensive to make. Second, a
recent systematic review of studies reporting on the costs
of administering biologics within the United Kingdom
(UK) National Health Service (NHS) identified possible
trade-offs between acquisition and administration costs: a
drug that appears cheap to buy may (in the long-run) have
higher total healthcare delivery costs as more NHS re-
sources are spent on drug administration. The budgetary
impact of a biologic with high acquisition costs but
relatively low administration costs could be the same as or
lower than that of a less expensive biologic with higher
administration costs. The study also found that there are
inconsistencies in how studies define administration costs
and consequently, differences in the type of costs included
or excluded from estimates of drug administration costs
[3]. These differences in what cost items are included or
excluded means some of the reported differentials in
administration costs for biologic drugs may not be real
and cannot be used unreservedly in economic analyses.
Once differences in cost estimates simply reflect differ-
ences in methods of measurement, one cannot tell for
sure whether trade-offs exist between administration costs
and drug acquisition costs or not; and to what extent
administration costs could influence conclusions reached
about cost-effectiveness.
Taking into account these points, we evaluate varia-
tions in the administration costs for a sample of eighteen
biologic drugs listed for use in the UK NHS, taking care
to ensure consistent inclusion or exclusion of all relevant
costs related to drug administration. We do this to ensure
very little variation in drug administration costs can be
attributed to differences in the method of measurement.
We develop an administration-cost algorithm to help
manufacturers predict, prior to market launch, the admin-
istration costs associated with their formulation choice for
each biologic drug candidate in their portfolio. We believe
this, together with manufacturers’ expectations of productprices, should help them consider the possible trade-offs
between drug acquisition and administration costs; and
generate credible estimates of total healthcare delivery
costs of their drug products and the likelihood that these
products will receive favourable recommendations from
healthcare payers.
The paper is structured as follows. We first describe in
Section Methods our methodological approach, under-
lying assumptions made in our analyses, and the data
sources used. This is followed by Sections Results and
Discussion with our results and discussion points. Section
Conclusions completes the paper with our conclusions.
Methods
To avoid overcomplicating our analyses, we will assume
clinical outcome neutrality; that is, for any comparison
of different modes of administering a biologic drug,
there are no differences in net health benefits (i.e., efficacy
minus safety concerns) or that differences in net health
benefits have no bearing on the magnitude or variation in
administration costs. For example, differences in the inci-
dence and severity of adverse events between two or more
formulations of a given biologic drug will have no bearing
as to how much is spent on drug administration costs. We
also ignore other costs associated with disease management.
Identifying and measuring administration costs
From an economic perspective, costs measured should
reflect the opportunity costs of NHS resources deployed
in administering biologic drugs that could otherwise have
been used elsewhere had the drug in question not been
administered. An accurate measurement of drug adminis-
tration costs thus requires identifying all resources that
will be expended or the ‘cost centres’ where resources will
be consumed and costs incurred [4]. To identify the ‘cost
centres’ related to the administration of biologic drugs
(from a healthcare payer perspective), we employ the
framework described by Tetteh and Morris [3] that makes
a distinction between the proximal costs of drug admi-
nistration and the costs of physical administration. In that
framework (see Figure 1), proximal administration costs
(Pc) refer to costs incurred before or after physical ad-
ministration of the drug into the body whilst physical
administration costs (PAc) refer to the costs of physically
introducing the drug into a patient via one of the estab-
lished routes for administration. Each component labelled
in that framework constitutes a (micro-level) cost centre
where resources are consumed and costs incurred.
We use this framework to ensure consistency in what
type of administration costs are included or excluded in
the analysis. Using a common yardstick should support
(1) complete or near complete accounting of the oppor-
tunity costs associated with drug administration, and (2)
“apples to apples” comparison of the administration costs
Proximal costs.
1. GP and clinic visits (outpatient and/or 
inpatient attendance)
2. Costs of education or training for self-
administration
3. Costs of pre-therapy counselling
4. Pharmacy costs (inventory, preparation 
and dispensing)
5. Pre-treatment medication costs
6. Costs of post-treatment, progress checks 
7. Cost of (laboratory) tests, assessment or 
evaluations.
Costs of physical administration.
1. Staff (doctor/nurse) costs
2. Cost of equipment and consumables
3. Cost of concomitant medications.
Components of drug 
administration costs
Figure 1 Framework of drug administration costs.
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tration costs can be attributed to the method of measure-
ment. For the same reasons, we defined a common time
frame over which drug administration costs will be esti-
mated. We chose to evaluate annual costs of drug admin-
istration costs as this fitted well with the dosing regimens
of all products in our sample. For simplicity, we base our
analysis on a single patient who successfully completes a
single full treatment course over a 12 month period. It
might be argued that this will introduce bias against
biologics indicated for an acute illness with typically
‘short’ treatment episodes. However, extending the
time frame beyond one-year period will actually amplify
the cost differences between acute and chronic biologics
whilst a 6-month period will not fit with the dosing regi-
men of some of the products in our sample. What is more,
we do not consider repeat treatment episodes over the
one-year period. Hence, our estimates of annual drug
administration costs should not be biased against biologics
indicated for acute illnesses.
Product sample and dosing regimens modelled
Our analysis makes use of an unbalanced sample of 18
therapeutically-active biologics; of which eight are admin-
istered intravenously, eight given by subcutaneous delivery
and two given intramuscularly. Within this sample, fifteen
of the products are humanized monoclonal antibodies
(mAb) with the remainder comprising of one fragmented
monoclonal antibody (fAb), a fusion protein and an inter-
feron protein. The characteristics of this product sample
are presented in Table 1. We make no argument that this
sample is representative of all existing or emergent bio-
logics or macromolecular therapies.To estimate the costs of administering the biologic
drugs in our sample, some idea or knowledge of the
dosing regimen for patients considered eligible to receive
a given biologic drug is needed. We follow the dosing regi-
men indicated by the marketing authorisation for a given
biologic drug, gathering this information from the posol-
ogy described in the drug’s package inserts, the summary
of product characteristics (SmPC) posted on the European
Medicines Agency (EMA) website; the British National
Formulary (BNF) or the electronic Medicines Compen-
dium (eMC). Obviously, within UK NHS settings, the
prescribed pathway suggested by the regulatory license or
marketing authorization may not necessarily coincide with
actual clinical practice – bearing in mind possible gaps
between recommendations in HTA guidance or clinical
guidelines and implementation of these recommendations
in routine practice; as well as practice-specific watch-and-
wait treatment strategies. To avoid the complexity intro-
duced by what happens in routine clinical practice, we
simply modelled the dosing instructions given in the prod-
ucts’ package inserts or the SmPC. For this, we assumed
continuous dosing of a given biologic for the whole year
unless the marketing authorization or SmPC clearly states
the maximum number of doses or recommended duration
of treatment. This is because we found it hard to make
any unquestionable assumption about the proportion of
treatment-responders and non-responders. The dosing
regimens modelled will be found in Additional file 1:
Appendix A.
Analysis
We first conducted a deterministic analysis with the
estimated costs of drug administration disaggregated into
Table 1 Characteristics of product sample
Product name Product type Clinical indication considered Disease type
Biologics given intravenously
Basiliximab†, Simulect® mAb Prophylaxis of acute organ rejection in allogeneic renal transplantation. Acute
Bevacizumab, Avastin® mAb First-line treatment of adult patients with non-small cell lung cancer. Chronic
Cetuximab, Erbitux® mAb Treatment of epidermal-growth-factor-receptor (EGFR)-expressing,
Kirsten Rat Sarcoma-2 (KRAS) wild-type metastatic colorectal cancer.
Chronic
Infliximab, Remicade® mAb Treatment of active rheumatoid arthritis that is unresponsive to disease
modifying anti-rheumatic drugs (DMARDs) or those with severe active
disease not previously treated with methotrexate (MTX) or DMARDs.
Chronic
Oftamumab†, Arzerra® mAb Treatment of chronic lymphocytic leukaemia that is refractory to
fludarabine and alemtuzumab.
Chronic
Panitumumab, Vectibix® mAb Treatment of wild-type KRAS metastatic colorectal cancer. Chronic
Tocilizumab, Actemra® mAb Treatment of moderate-to-severe active rheumatoid arthritis. Chronic
Trastuzumab, Herceptin® mAb Treatment of advanced and metastatic breast cancer. Chronic
Biologics given subcutaneously
Adalimumab†, Humira® mAb Treatment of moderate-to-severely active Crohn’s disease in children. Chronic
Canakinumab†, Ilaris® mAb Treatment of cryopyrin-associated periodic syndromes (CAPS) in adults. Chronic
Certolizumab pegol†, Cimzia® fAb Treatment of moderate-to-severe active rheumatoid arthritis in adults
when response to DMARDs including MTX has been inadequate.
Chronic
Denosumab†, Prolia® mAb Treatment of osteoporosis in post-menopausal women at increased
risk of fractures.
Chronic
Etanercept†, Enbrel® Fusion protein Treatment of active and progressive psoriatic arthritis that has not
responded adequately to DMARDs.
Chronic
Golimumab†, Simponi® mAb Treatment of moderate-to-severe active ankylosing spondylitis. Chronic
Omalizumab†, Xolair® mAb Management of immunoglobulin-E mediated asthma. Chronic
Ustekinumab†, Stelara® mAb Treatment of moderate-to-severe plaque psoriasis. Chronic
Biologics given intramuscularly
Palivizumab†, Synagis® mAb Prevention of serious lower respiratory tract disease caused by respiratory
syncytial virus (RSV) in children at high risk of RSV disease.
Acute
Interferon beta-1a†, Avonex® Interferon protein Treatment of relapsing multiple sclerosis in adult patients, i.e., two or
more acute exacerbations in the previous three years without evidence
of progressive disease.
Chronic
Notes: †refers to biologics that are sold bundled with some of the equipment and consumables used in drug administration.
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the drug. We used Figure 1 as a guide to selecting which
cost item to include as long as we found publicly-available
data for that cost item. Our analysis was done using a
spreadsheet model with data inputs from the BNF and
eMC, the NHS Reference Costs 2011-2012, the NHS
electronic Drug Tariff and the 2012 edition of the PSSRU
(Personal Social Services Research Unit) Costs for Health
and Social Care, and from published and grey literature. A
summary of the data inputs will be found in Additional
file 2: Appendix B. One issue with our deterministic ana-
lysis is the well-known fact that there is: (1) uncertainty in
the incidence and severity of illness and for that matter,
demands for health intervention using biologic drugs plus
(2) uncertainty with regards to treatment outcomes, which
fuels future demands for healthcare intervention; for ex-
ample, dose reduction or escalation; modifications to dos-
ing regimens and treatment protocols and/or deploymentof alternative (salvage) interventions in complementary or
substitutive ways [5,6]. For this reason, the quantity and
costs of NHS resources expended on the administration
of biologic drugs cannot be described by fixed values –
considering also deviations of what happens in routine
clinical practice from the EMA-approved posology.
We attempt to resolve this issue by introducing param-
eter uncertainty into our analysis – by fitting a gamma
distribution to the deterministic estimates of Pc as well as
PAc, and running 1000 Monte Carlo simulationsa for each
product. Note that the choice of a gamma distribution is
not arbitrary but reflects the observation that healthcare
resource use and costs are skewed with non-negative
values ranging from zero to positive infinity. As argued by
Nixon & Thompson [7], skewed parametric (gamma,
log-logistic, lognormal) distributions fit medical cost data
better than a normal distribution and should in principle
be preferred for estimation. What is not clear, however, is
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chose a two-parameter (α, β) gamma distribution, and
given the absence of real-life data that reflects the uncer-
tainty of healthcare demands requiring intervention with
biologics, we adopted the simplest assumption that the
mean and SE for administration costs for any given bio-
logic drug in our sample is the same (see Briggs et al. [8]).
That is, we apply a gamma distribution defined by α = 1
and β =ADMINCOST. We do not expect this to introduce
any systematic bias as the assumption will apply to all pro-
ducts within our sample.
From the synthetic dataset generated, we estimated
the proportion of total administration costs that is due
to Pc or PAc for our sample of biologic drugs (categorized
according to their respective routes of administration) by
graphing a log-log plot of Pc versus PAc. We took logs
of Pc and PAc because of the skewness of a gamma-
distributed cost data and to narrow down the range of
(large) values. We then estimated the proportion of sim-
ulations where the ratio of proximal costs to physical
administration costs (PAc/Pc) is greater than or equal to 1.
The essence of this exercise is to identify the source of ad-
ministration cost savings from changes in drug formulation
and manufacturing.
Identifying the algorithm
Recall that one of our study objectives is to develop an
algorithm that will allow manufacturers to predict how
administration costs change with how they choose to
manufacture and formulate a given biologic drug candi-
date. On a priori grounds, we defined this algorithm as
a sample regression function linking drug administration
costs (ADMINCOST) and a number of independent
explanatory variables (X). The explanatory variables we
chose are those that we believe (bio)pharmaceutical man-
ufacturers will have some information on, or an idea of, as
they work on a number of promising biologic drug candi-
dates, and decide which candidates to take forward to the
next stage of process R&D or product development, and
which ones to reserve as contingency or backup options.
Given the expected skewness of our simulated data for
ADMINCOST (on the raw scale), we estimate the fol-
lowing with a log-transformed dependent variable:
ln ADMINCOSTð Þ ¼ αþ β0SUBCUTANEOUS
þ β1INTRAMUSCULAR
þ β2DOSFREQ
þ β3PRODUCTBUND
þ β4INDICATN
þ β5DOSFREQ2
þ β6DOSFREQ:INDICATN þ 
The intercept is α and the error term (  ) repre-
sents any unexplained variation in administration costs.SUBCUTANEOUS is a dummy variable that takes the
value of one if a product is given subcutaneously and zero
otherwise. Equally, the dummy variable INTRAMUSCU-
LAR takes on the value of one if a product is administered
intramuscularly and zero otherwise. Intravenous adminis-
tration is therefore the baseline, benchmark or reference
category. We do this because for most biologics, intra-
venous infusion is the default (conventional) drug delivery
or formulation choice given the fragility and poor oral
bioavailability of macromolecular proteins. The variable
DOSFREQ refers to the frequency (intensity) of dosing,
which we define as the number of ‘unit administrations’
in a given year. PRODUCTBUND is a zero-one dummy
variable indicating whether a given biologic product is
sold together with some of the equipment and consum-
ables used in drug administration (1) or not (0). Similarly,
INDICATN is a zero-one dummy variable indicating
whether a biologic drug is for the management of an acute
illness (0) or for a chronic illness (1). The interaction term
DOSFREQ.INDICATN is intended to capture the notion
that treatments for acute illnesses tend to have less ‘com-
plex’ dosing regimens compared to those for chronic
illnesses; and the quadratic term DOSFREQ2 is intended
to determine whether the marginal effects of DOSFREQ
are increasing or diminishing as the frequency (intensity)
of dosing increases.
We estimate the four nested models using linear
ordinary least squares (OLS) regression. We labelled
the four nested models as A, B, C and D – all of which
rely on different combinations of the explanatory vari-
ables defined above. We designate C as the full unre-
stricted model as it includes all the explanatory variables
above.Robustness checks
A well-known problem with OLS regression using a log-
transformed dependent variable is that retransformation
of ln dADMINCOST to the raw untransformed scale gives
the geometric mean for dADMINCOST (which is often
close to the median) rather than the arithmetic mean,
the parameter of interest. (The hat on ADMINCOST
indicates an estimated or predicted value). The problem
is resolved by using what is called a smearing factor to
minimize the prediction error. The name is derived from
the fact that the factor distributes (smears) the ‘excess’
or prediction error in one observation to other obser-
vations proportionally when adjusting unlogged median
estimates to unlogged mean estimates. Generally, this
takes the form: dADMINCOST ¼ exp X βk∧
 
•ф
∧
, where
ф
∧
is the smearing factor. We looked at three ways of
deriving less-biased smearing estimates of ADMINCOST
(on the raw untransformed scale).
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ory estimates’ that are derived under the assumption
that the error term for ln dADMINCOST is normally
distributed, in which case the smearing estimate of
ADMINCOST ¼ exp Xβ^k þ 0:5σ^2
 
where bσ2 is the
square of SE(ln dADMINCOST ) and the smearing factorbф ¼ exp 0:5σ^2  . If errors are not normally distributed
but are homoscedastic (i.e., constant variance), then the
second method, which uses non-parametric (sub-group
specific) smearing factors can be used to minimize pre-
diction errors. The non-parametric smearing factor is
given by: bф ¼ N−1XN
i¼1 exp
ciÞð , where N is the number
of observations and bi is the log-scale residuals from the
regression. When the errors are heteroskedastic (i.e., non-
constant variance), or they depend on the explanatory
variables, it is “better” to use a subgroup-specific smearing
factor for each intravenous, subcutaneous or intramus-
cular product category [9,10,11]. The third method uses a
regression-through-the-origin approach suggested by
Wooldridge [12]. This is as follows: obtain for each ob-
servation the naïve estimates cmi ¼ exp dlnADMINCOST ;
then perform a regression of ADMINCOST on cmi
through the origin and obtain the only coefficient bα0
as the smearing factor.
Irrespective of the smearing factor used, its value in
minimizing prediction error depends crucially on the
presence and nature of heteroskedasticity in the log scale
residuals. For example, the subgroup smearing factors
assume that log scale heteroskedasticity varies across the
mutually-exclusive subgroups specified. If, however, het-
eroskedasticity varies according to one or more (con-
tinuous, discrete or interacted) explanatory variables in
the log-OLS regression, then we will have smearing esti-
mates of ADMINCOST that are still biased. It is possible
to run an auxiliary regression of the heteroskedastic
variance as a function of one or more of the explana-
tory variables, i.e., bф ¼ exp biÞ ¼ ρ Xð Þð ; where ρ is a
vector of regression coefficients. This crucially de-
pends on how much of the heteroskedastic variance
is explained by the chosen set of explanatory vari-
ables. Generally, this auxiliary-regression approach is
thought to be cumbersome and there is no simple fix
if the form of heteroskedasticity is unknown. An alterna-
tive estimator, however, exists in the form of generalized
linear modelling (GLM) to overcome the retransformation
problem.
GLM does this by directly and independently specifying:
(1) a link function between the raw scale ADMINCOST
and the linear index (Xβk), and (2) a family of parametric
distributions to reflect any heteroskedastic relationshipbetween the raw scale error variance and dADMINCOST ;
i.e., var ADMINCOSTð Þ≅ φ: dADMINCOSTh iδ , where δ
is the over-dispersion parameter and φ is a constant
[11,13,14]. Independent specification of the link func-
tion (i.e., the scale of estimation) and family distribu-
tions (i.e., the variance function) under GLM allowsdADMINCOST to be estimated directly (or from the
natural exponent of ln dADMINCOSTÞ without the
need for smearing factors. In most applications, three
types of link functions are specified: “identity”, “log”
and “power”. Here an identity link specifies the fol-
lowing relationship: dADMINCOST ¼ Xβk ; and the log
links takes the form dADMINCOST ¼ exp Xβk  . The
family distributions commonly investigated or used to
model heteroskedasticity are Gaussian if the param-
eter δ = 0; Poisson if δ = 1, Gamma or heteroskedastic
normal if δ = 2 and inverse Gaussian if δ = 3. The ap-
propriate family distribution is often identified using
the so-called modified Park test, that involves a log-
gamma GLM regression of var(ADMINCOST) on lndADMINCOST . The coefficient on ln dADMINCOST
approximates bδ.
Notwithstanding, GLM is known to suffer prediction
losses if one has heavy tailed data (kurtosis) even after
log retransformation of the dependent variable. GLM
prediction losses (relative to the log-OLS estimator) in-
creases with the coefficient of kurtosis of the log scale
error or when the true underlying model is a log normal
with constant error variance (on the log scale). For this
reason, Manning and Mullahy [11] and Manning et al.
[15] suggest, before using GLM, to assess the form of
the log-scale residuals of the OLS regression. If the log-
scale residuals are heavy-tailed: leptokurtotic (coefficient
of kurtosis > 3) or the log-scale error variance (which in-
creases with skewness of the dependent variable) is
greater than or equal to one, then log-OLS regression
(with the appropriate retransformation for heteroskedas-
tic variance) may be preferable to GLM. If, however, the
log-scale residuals are both leptokurtotic and heteroske-
dastic, then the results from both log-OLS regression
and GLM should be reported and compared. If the prob-
ability density function (pdf) of the raw-scale residuals
from one of the GLM estimators with a log link are not
bell-shaped or skewed bell-shaped, then log-OLS models
may be less precise. If the pdf of the raw-scale residuals
from GLM are monotonically declining then the appro-
priate family distribution should be identified using a
modified Park test.
Still another problem with GLM is that independent
specification of the link and variance functions could
lead to bias and estimation inefficiency. Whilst the
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modified Park test, one obtains different regression coef-
ficients and inferences on incremental/marginal effects
as the link function selected varies. We therefore con-
sider an extended estimating equations (EEE) version of
GLM (also referred to as power-GLM or PGLM) that
doesn’t require a priori specification of the link and
variance functions. The PGLM/EEE estimator utilizes
the following Box-Cox transformation for the link
function:
Xβk ¼
dADMINCOSTλ−1 =λ; if λ≠0
ln dADMINCOST ; if λ ¼ 0
8><
>:
Two broad family distributions can be specified:
(1) a “power variance” family characterised by:
var ADMINCOST ; θ1; θ2ð Þ ¼ θ1 dADMINCOST θ2 and (2) a
“quadratic variance” family characterised by: var
ADMINCOST ; θ1; θ2ð Þ ¼ θ1 dADMINCOST  þ θ2 dADMINCOSTð Þ2,
where θ1, θ2 together index the appropriate variance
distribution for the dataset analysed. By simultan-
eous specification of the link and variance functions,
and joint estimation of the parameters above,
PGLM/EEE is a more flexible and robust estimator
especially when no specific link or variance function
can be identified. For example, if the GLM over-
dispersion parameter bδ is a non-integer, then choos-
ing the closest family distribution could lead to effi-
ciency losses [16,17].
All our analyses were conducted in Microsoft Excel
and STATA v. 11.
Results
Simulations
Figure 2 below shows the log-log plot of Pc versus PAc
from outputs of the simulations for performed for our
product sample. The simulations confirm our expecta-
tions that the costs of administering biologics subcuta-
neously or intramuscularly are mainly from the costs
incurred before or after physical administration of a
drug – although some deviations (inconsistencies) are
evident. Observe that for biologics administered subcuta-
neously or intramuscularly, most of the simulations lie
above the 45° line, which equates Pc to PAc. In contrast,
the simulations for intravenous biologics fall on either side
of the 45° line with the exception of two drugs: tras-
tuzumab and basiliximab. For trastuzumab, most of the
simulations fall above the 45° line, which suggests that the
associated proximal cost of administering this drug is
higher (relative to the physical administration costs). In
the case of basiliximab, most the simulations fall belowthe 45° line indicating that physical administration costs
are higher for that drug.
Although Figure 2 provides an idea of the general
location of the simulated values for Pc and PAc for each
product category, the overlap of data points makes it
difficult to tell the pattern for each biologic product.
The exact percentage of simulations with the ratio PAc/
Pc ≥ 1 can, however, be easily computed from the synthe-
sized data. For the intravenous products, the percentage
of simulations with the ratio PAc/Pc ≥ 1 is as follows:
basiliximab (95%), bevacizumab (35%), cetuximab (28%),
infliximab (28%), oftamumab (49%), panitumumab (46%),
tocilizumab (49%) and trastuzumab (9%). For the sub-
cutaneous products, this is as follows: adalimumab (2%),
canakinumab (7%), certolizumab pegol (1%), denosumab
(22%), etanercept (20%), golimumab (22%), omalizaumab
(33%) and ustekinumab (1%). For the intramuscular bio-
logics, we have 17% for palivizumab and 25% for inter-
feron beta-1a. In general, we can say that a higher
proportion of the administration costs of biologic drugs
given subcutaneously or intramuscularly come from the
proximal costs incurred before or after drug administra-
tion while for intravenous products, costs are incurred in
both cost centres.
An aggregated picture of the simulation outputs above
is presented below in the histogram with a kernel density
overlay (Figure 3). This shows the empirical distribution
of ADMINCOST values averaged over the 1000 simula-
tions for each of the 18 sample products. It is right skewed
(coefficient of skewness = 2.3568) with heavy tails (coeffi-
cient of kurtosis = 8.6048) – thus confirming the overcon-
centration of gamma-distributed values. The minimum
and maximum values are £35.58 and £18,348.85 respect-
ively; and as often observed of skewed and kurtotic data,
the median ADMINCOST (£1414.79) is less than half the
mean (£3075.77) and the standard deviation (£4477.94) is
greater than the mean.
A different picture of the distribution of simulated
ADMINCOST values is shown in Figure 4 above. This
confirms our prior expectations that the costs of admin-
istering biologics given subcutaneously or intramuscu-
larly are lower than that of biologics given intravenously.
However, the numbers on top of each stacked bar in
Figure 4 suggests that one has to be cautious when using
cost per unit administration to illustrate variations in
biologic drug administration costs. Tetteh and Morris
[3], for instance, using a selected set of studies offering a
comparable scale of measurement for cost per unit
administration, report that the administration costs of
intravenous biologics appear to be six to eight times that
of biologics given subcutaneously or intramuscularly.
Differences observed (on the basis of cost per unit ad-
ministration) disappear, are attenuated or reversed when
one considers drug administration costs over a defined
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Figure 2 Simulation outputs.
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frequency is, at least, one of the reasons why cost per
unit administration may not be an appropriate indicator
of the variation in administration costs. This unfortu-
nately still leaves unanswered the question: by how
much do administration costs differ between biologics
given intravenously, subcutaneously or intramuscularly?
Administration cost algorithm
To answer the question above, we turn to the results
of our regression-based algorithm shown in Table 2.Note that the results are for ln dADMINCOST, notdADMINCOST. The regression coefficients, nevertheless,
carry the desired information as to the link between
biologic administration costs and the frequency or
route of drug administration. As mentioned earlier,
we estimate four nested models A, B, C and D with C as
the full unrestricted model. From Table 2, model C
offers the best fit with our simulated dataset, having
the highest adjusted R2, lowest sum of squared residuals
and the lowest prediction variance, i.e., the square of
SE(ln dADMINCOST ). To ensure robustness, we explore
Figure 3 Distribution of average simulated ADMINCOST.
0 5 10 15 20
Basiliximab
Bevacizumab
Cetuximab
Infliximab
Oftamumab
Panitumumab
Tocilizumab
Trastuzumab
Adalimumab
Canakinumab
Certolizumab
Denosumab
Etanercept
Golimumab
Omalizumab
Ustekinumab
Palivizumab
Interferon
Proximal Costs
Physical Administration Costs
SC
IM
IV
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administration; values on top of each stacked bar represents DOSFREQ: the number of unit administrations per year; the values in brackets and
pound currency refer to the cost per unit administration.
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Table 2 Identifying the algorithm
Dependent variable: lnADMINCOST
Model A Model B Model C Model D
Independent variables bβk (SE) bβk (SE) bβk (SE) bβk (SE)
SUBCUTANEOUS -3.2858 (0.57)*** -2.6161 (1.106)** -3.2073 (0.902)*** ―
INTRAMUSCULAR -2.4097 (0.90)** -2.2784 (1.219)* -5.1856 (1.335)*** ―
DOSFREQ -0.0046 (0.011) -0.0025 (0.012) 0.4206 (0.18)** -0.1022 (0.179)
PRODUCTBUND ― -0.7395 (1.129) 0.4133 (0.928) -2.7416 (0.678)***
INDICATN ― -1.0527 (1.219) -0.2084 (1.467) -3.7195 (1.693)**
DOSFREQ2 ― ― -0.00105 (0.0003)*** -0.00075 (0.0004)*
DOSFREQ.INDICATN ― ― -0.3126 (0.172)* 0.17 (0.183)
Intercept 8.6223 (0.45)*** 9.6888 (1.274)*** 7.1058 (1.521)*** 11.305 (1.685)***
Regression statistics
R2 (Adjusted R2) 0.7188 (0.6586) 0.7376 (0.627) 0.8881 (0.8098) 0.6957 (0.5689)
F-statistic (>c) 11.9313 (>3.1122) 6.7151 (>2.9961) 11.3369 (>3.0717) 5.4864 (>2.9961)
SSR (N) 17.8023 (18) 16.6714 (18) 7.0858 (18) 19.2688 (18)
SE( blnADMINCOST ) 1.1276 1.1787 0.8418 1.2672
F-ratio (>c) 3.781 (<3.478) 6.764 (>4.1028) ― 10.3161 (>4.1028)
Notes: bβk = regression coefficients; ***p< 0.01; **p< 0.05; *p< 0.10; SE = default standard error; F-statistic = F-test for overall significance of the regression; c = critical
value for F-test; SSR = residual sum of squares; N = number of observations; F-ratio= F-test for comparison with model C; c = critical value for the F-test; SUBCUTANEOUS =
dummy variable for subcutaneous delivery; INTRAMUSCULAR = dummy variable for intramuscular delivery; DOSFREQ = dosing frequency; PRODUCTBUND=dummy
indicating whether the drug product is sold as a bundled product with some of the equipment and consumables used in drug administration; INDICATN = dummy for type
of illness a product is clinically indicated for.
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are shown in Table 3 below.
We found that the raw-scale residuals from a GLM
with log-link and gamma family distribution did not
exhibit a monotonically declining pdf albeit the residuals
were kurtotic (coefficient of kurtosis = 4.3907). The resi-
duals from a standard OLS regression on ADMINCOST
were also leptokurtotic (coefficient of kurtosis = 5.080),
and remained kurtotic even after log transformation of
ADMINCOST (coefficient of kurtosis = 3.1648). Whilst
tests for normality of the OLS residuals indicate non-
normal data, we could not reject the null of normal data
for the residuals from the log-OLS regression (at the 5%
significance level). Variants of the Breusch-Pagan test for
heteroskedasticity of the log-OLS residuals showed that,
at the 5% significance level, we cannot reject the null of
constant variance (lowest p value = 0.078). Further, a
standard Park test, i.e., an auxiliary regression of the
form exp biÞ ¼ ρ Xð Þð indicated that none of the explana-
tory variables are statistically significant predictors of
log-scale residuals. The log-error variance (i.e., the mean
squared error) of the log-OLS model C, however, was
less than one – see Table 2. As noted by Manning &
Mullahy [11] and Manning et al. [15], these statistics
affect the choice between log-OLS and GLM estimators.
A modified Park test following the log-gamma GLM
suggests that we cannot reject a Gaussian, poisson,
gamma or inverse Gaussian distribution for the GLMvariance function. Besides not being able to identify the
appropriate GLM link and variance functions, we also
know GLM suffers precision losses in the face of heavy-
tailed residuals. In fact, a joint estimation of the link and
variance functions by PGLM/EEE (QV) rejected a log-
gamma GLMb. Whilst the regression coefficients from
the log-gamma GLM and the PGLM/EEE (QV) are not
entirely consistent, the initial coefficient values used in
the PGLM/EEE are derived from a gamma GLM with a
log-link. Based on the estimated values for bλ and bθ2, the
PGLM/EEE (QV) model identifies NLLS or a log-linear
model with Gaussian variance function as the best
model fit to our synthesized dataset. We implement the
latter using the GLM equivalent of a log-OLS regression
as we found that GLM with log-link and Gaussian vari-
ance function failed Pregibon’s link test. We conjecture
that this is because the natural (canonical) link function
for a Gaussian family distribution, especially with small
samples, is an identity one – not to mention the pre-
cision losses from GLM in the face of heavy-tailed
residuals.
Note, however, that the log-gamma GLM, PGLM/EEE
(QV) and identity-Gaussian GLM models listed in Table 3
all passed the following goodness-of-fit tests: Pearson’s
test for correlation between raw-scale predictions and
residual errors, Pregibon’s link test for functional-form
specification; and modified Hosmer-Lemeshow tests for
systematic patterns in the error residuals. Considering the
Table 3 Alternative estimators for model C
Dependent variable: ADMINCOST or lnADMINCOST
GLM (log, Gamma) PGLM/EEE (QV) GLM (identity Gaussian) NLLS
Independent variables bβk (SE) bβk (SE) bβk (SE) bβk (SE)
SUBCUTANEOUS -2.8255 (0.314)*** -2.6618 (0.369)*** -3.2026 (0.363)*** -3.2026 (0.474)***
INTRAMUSCULAR -5.0158 (0.393)*** -4.7495 (0.609)*** -5.2737 (0.509)*** -5.2737 (0.664)***
DOSFREQ 0.4015 (0.042)*** 0.3754 (0.059)*** 0.428 (0.054)*** 0.428 (0.07)***
PRODUCTBUND 0.2364 (0.198) 0.2336 (0.19) 0.404 (0.269) 0.404 (0.35)
INDICATN -0.2352 (0.145) -0.2592 (0.133)* -0.2896 (0.183) -0.2896 (0.283)
DOSFREQ2 -0.00102 (0.0002)*** -0.00093 (0.0001)*** -0.00106 (0.0002)*** -0.00106 (0.0003)***
DOSFREQ.INDICATN -0.3004 (0.021)*** -0.2775 (0.053)*** -0.3173 (0.028)*** -0.3173 (0.036)***
Intercept 7.3703 (0.257)*** -0.6008 (0.264) 7.1499 (0.349)*** 7.1499 (0.455)***
Regression statistics
Log pseudo-likelihood (AIC) -143.3921 (16.377) — -16.8641 (2.3182) —
OD parameter: bδ 95% CIð Þ 1.589 (1.251, 1.921) — — —
Link parameter: bλ 95% CIð Þ — 0.078 (-0.2361, 0.3921) — —
VF parameter: bθ1 95% CIð Þ — 0.0304 (-0.0038, 0.0646) — —
VF parameter: bθ2 95% CIð Þ — 0.0899 (-0.0038, 0.1836) — —
R2 (Adjusted R2) — — 0.8923 (0.8285) 0.8923 (0.8692)
Notes: bβk = regression coefficients; ***p < 0.01; **p < 0.05; *p < 0.10; SE = heteroskedastic-robust standard error; CI = confidence interval; SUBCUTANEOUS = dummy
variable for subcutaneous delivery; GLM = generalized linear modelling; PGLM = Power-GLM; EEE = extended estimating equations; QV = quadratic variance
function; NLLS = non-linear least squares; INTRAMUSCULAR = dummy variable for intramuscular delivery; DOSFREQ = dosing frequency; PRODUCTBUND = dummy
indicating whether the drug product is sold as a bundled product with some of the equipment and consumables used in drug administration; INDICATN = dummy for
type of illness a product is clinically indicated for; AIC = Akaike Information Criterion; OD = over-dispersion; VF = variance function.
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kurtosis and heteroskedasticity; the consistent coefficients
from NLLS and the GLM equivalent of log-OLS (plus
the observation that none of the explanatory variables
in model C are statistically-significant predictors of
heteroskedastic variance if it exists), we believe that
the underlying true model is closer to a log-normal
with homoscedastic variance on the log-scale. We focus
therefore our attention on columns 3 and 4 of Table 3: the
log pseudo-likelihood and AIC indicates that an identity-
Gaussian GLM for lnADMINCOST is a better model fit
than a log-gamma GLM for ADMINCOST.
But before proceeding, it is important first to remind
ourselves that the reference category is biologic drugs
formulated for intravenous administration. The intercept
from model C regression represents lnADMINCOST for
an intravenous biologic drug indicated for an acute
illness and not sold as a bundled product. This, however,
carries no particularly meaningful information as it re-
quires DOSFREQ to be zero. There is no point manufac-
turing and formulating a biologic drug if it is not going
to be used. Second, the regression coefficients are semi-
elasticities: they represent the ceteris paribus percentage
change in dADMINCOST given a unit change in the expla-
natory variables [18,19,12]. Wooldridge [12] suggest
that for continuous variables, the marginal effectspercentage changed in dADMINCOST  ¼ 100 • bβk for
a unit change in the explanatory variable X. For
dummy variables, the incremental effects percentageð
changed in dADMINCOSTÞ ¼ 100 • exp bβk
 
−1
h i
. In this
section, we follow Kennedy’s [18] argument that for dummy
variables in a log-OLS regression, the incremental effect
is given by: 100•[exp{( bβk ) – 0.5(SE( bβk )2} – 1]. This
corrects for small sample bias.
From Table 3, the coefficient for SUBCUTANEOUS
has the expected sign and it is statistically significant.
This suggests that formulating a biologic drug candidate
for subcutaneous rather than intravenous delivery, hold-
ing all else constant, reduces dADMINCOST by appro-
ximately 96.19% (=100•[exp(-3.2026 – .5(.3632)) – 1]).
The coefficient for INTRAMUSCULAR also has the
expected sign and it is statistically significant. This
suggests that formulating a biologic drug candidate for
intramuscular rather than intravenous delivery will re-
duce dADMINCOST by approximately 99.55% (=100•[exp
(-5.2737 – .5(.5092)) – 1]) holding all else constant.
These percentages do not mean that intravenous prod-
ucts account for over 99% of the variation in administra-
tion costs for our product sample – it only refers to
isolated incremental effects of the administration-route
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effects of SUBCUTANEOUS and INTRAMUSCULAR
( bβ0− bβ1 ) is statistically significant (p value = 0.0035).
That is, there is ‘strong’ evidence of a reduction in
ADMINCOST in switching from subcutaneous to
intramuscular formulation at the 5% significance level.
Note that in models A and B (Table 2), the coefficients for
the administration-route variables have the expected signs;
they are of the same order of magnitude as the coefficients
for model C but are not always statistically significant at
the 5% level. We consider that the administration-route
variables explain a lot of the variation in lnADMINCOST
and ADMINCOST.
The coefficient for the DOSFREQ has the expected
sign and it is statistically significant but it should not
be interpreted in isolation given the quadratic term
DOSFREQ2 and the interaction term DOSFREQ.INDI-
CATN. The percentage change in dADMINCOST with a
unit change in DOSFREQ is not 42.8% (=100•.428). The
negative coefficient on DOSFREQ2 suggests that the mar-
ginal effect of DOSFREQ on ln dADMINCOST diminishes
with increases in dosing frequency. This curvilinear rela-
tionship is as follows:
∂ dlnADMINCOST =∂DOSFREQ ¼ bβ2−2 bβ5DOSFREQ− bβ6INDICATN
For an acute illness, INDICATN = 0 and the percent-
age change in ADMINCOST from moving from once a
year dosing to twice a year is 42.59% (=100•[.428 – 2
(.00106)(1)]). But moving from 100 to 101 unit adminis-
trations per year will only increase dADMINCOST by
21.6% (=100•[.428 – 2(.00106)(100)]). For a chronic
illness (INDICATN = 1), the corresponding percentage
change in dADMINCOST of moving from one to two
unit administrations per year is 10.86% and -10.13% for
moving from 100 to 101 unit administrations per year.
The latter result reflects the curvilinear relationship be-
tween ADMINCOST and DOSFREQ. Although the coef-
ficient on DOSFREQ suggests that increases in dosing
frequency should lead to increases in dADMINCOST , the
coefficient on DOSFREQ2 means that beyond some
positive value of DOSFREQ (a turning point), increases
in dosing frequency will be associated with lower drug
administration costs.
For biologics indicated for acute illnesses, this turning
point is achieved when DOSREQ is approximately 202
(= .428 divided by 2[.00106]) unit administrations per
year. This is roughly a four times a week dosing regimen
with perhaps a tapering off of dosing frequency due to
improved treatment response or concerns about adverse
events. For the two biologic drugs indicated for acute
illness, their unit administrations per year are far from202 so we can safely ignore what happens after the turn-
ing point. For biologics indicated for chronic illnesses,
this turning point is reached when DOSFREQ is just
over 52 (= [.428 – .3173] divided by 2[.00106]) unit ad-
ministrations per year, i.e., roughly dosing once weekly.
Only one of the chronic biologic drugs within our sam-
ple (etanercept) has a dosing frequency that greatly
exceeds this turning point. We can therefore ignore the
turning point knowing the source of this seemingly
counterintuitive observation. Indeed, a test for detecting
influential (outlier) observations indicated that only
one product (etanercept) had an absolute DFITS value
greater than twice the threshold of 1.333. (DFITS is the
scaled difference in predicted values of ADMINCOST
with and without the jth observation, in this case eta-
nercept). However, the curvilinear relationship between
ADMINCOST and DOSFREQ raises an interesting sce-
nario that, given the peculiar biophysical characteristics
and pharmacokinetic profiles of a biologic drug candi-
date, it is possible to have lower ADMINCOST when
DOSFREQ is higher relative to some appropriately
defined comparator drug.
For the PRODUCTBUND variable, we found that
whilst it did not reach statistical significance, the regres-
sion coefficient has the unexpected sign. The size of the
coefficient suggests that, holding all else equal, bund-
ling a biologic product with some of the equipment
and consumables used in drug administration increasesdADMINCOST by approximately 44.46% (=100•[exp(.404 –
.5(.26932)) – 1]). Since we cannot reject the possibility that
the coefficient for PRODUCTBUND is zero, we sought to
explore the dataset to see why we observe this result. It
turns out that the there is a non-trivial correlation be-
tween PRODUCTBUND and SUBCUTANEOUS (correl-
ation coefficient of .6325) and with INTRAMUSCULAR
(correlation coefficient of .25). Dropping the adminis-
tration-route variables in model D (Table 2) produced the
expected sign for PRODUCTBUND and it achieved statis-
tical significance. This suggests that bundling a biologic
product with some of the equipment and consumables
used for drug administration reduces dADMINCOST by
roughly 95% (=100•[exp(-2.7416 – .5(.678)2) – 1]). The
effect is similar to that of the administration-route vari-
ables. This makes sense as all the products in our sample
administered subcutaneously or intramuscularly are, by
definition, bundled with some of the equipment and con-
sumables used for administering drugs. Model D, however,
suffers from dropping the administration-route variables:
its adjusted R2 is the lowest (.5689).
The variable INDICATN also shows up with the
unexpected sign but it doesn’t reach statistical signifi-
cance in models B and C. This result seems counterintui-
tive considering the persistence of healthcare resource
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illnesses. In model D (Table 2), however, the variable
INDICATN reaches statistical significance. Again, we
explored our simulated dataset to find reasons why this
might be the case. It turns out that INDICATN is nega-
tively correlated with INTRAMUSCULAR (correlation
coefficient of -.4375) and positively correlated with
SUBCUTANEOUS (correlation coefficient of .3162).
We speculate that the net outcome of these opposing
effects is the reason why INDICATN has the negative
sign. In fact for the subgroup of intramuscular biologics,
there is only one product for acute illness and the other
for chronic illness. There are no subcutaneous biologics
indicated for acute illnesses in our sample. The apparent
counterintuitive result simply reflects the nature of the
product sample and simulated dataset. It might not neces-
sarily be observed with a different or updated product
sample.
Note that although the variables PRODUCTBUND
and INDICATN have unexpected signs and individually
they may not always reach statistical significance, they
are jointly significant in the presence of the other ex-
planatory variables in model C. That is to say, a reduced
form of the log-OLS model C that excludes these sta-
tistically insignificant variables will carry a lot more of
unexplained variation in ADMINCOST. As indicated by
the F-ratios for the comparisons of model A, B and D
with model C in Table 2, there is no justification for
excluding these statistically-insignificant variables.Validation
As discussed in Section Methods, one must proceed
with caution when using the algorithm based on the
log-OLS model C to predict the administration costs for
a biologic drug candidate. Specifically, one needs a
smearing factor to minimize prediction errors. We found
that Duan’s smearing factor for all product categories
was 1.204; and the subgroup-specific smearing factors
are as follows: 1.0206 for intravenous products, 1.3799
for subcutaneous products and 1.00 for intramuscular
products. The smearing factor from Wooldridge’s ap-
proach was 1.0287. To identify which of the methods of
deriving less biased OLS estimates of dADMINCOST is
best, we estimated the coefficient of determination (i.e., the
square of the correlation coefficient) between the smearing
estimates and simulated values for ADMINCOST. This
was .822675 for the ‘normal theory estimates’ , .822382 for
estimates derived using the subgroup-specific smearing
factors and .822675 for the Wooldridge approach. There is
therefore not much to choose from the three alternatives
but we prefer the subgroup-specific smearing factors as it
allows us to make cost predictions tailored to specific
product formulations; and because the residuals frommodel C exhibit statistically-insignificant heteroske-
dasticity that is not explained by any of the explanatory
variables.
To illustrate how the algorithm can be used to predict
administration costs, consider current attempts to refor-
mulate trastuzumab for subcutaneous delivery. This has
been made possible by the feasibility of manufacturing
highly-concentrated solutions for monoclonal antibodies
and co-formulation with an excipient, recombinant hu-
man hyaluronidase that dissolves subcutaneous tissues
for rapid drug absorption [20]. Let’s assume outcome
neutrality between subcutaneous and intravenous deliv-
ery of trastuzumab, and the same dosing frequency at
three-weekly intervals. Recent phase I trials suggest that
subcutaneous and intravenous trastuzumab have indeed
comparable efficacy and safety profiles [21]. Also sub-
cutaneous trastuzumab will, by definition, be available
as a bundled product: it is mostly likely to be sold to-
gether with an automated single-use injectable device
in place of manual administration with a syringe [20].
We know trastuzumab is indicated for a chronic illness
(see Table 1) so the annual ADMINCOST can be predic-
ted as follows:
dlnADMINCOSTIV ¼ 7:1499−3:2026 0ð Þ−5:2737 0ð Þ
þ :428 17:33ð Þ þ :404 0ð Þ
− :2896 1ð Þ− :00106 17:332 
− :3173 17:33ð Þ 1ð Þ
dADMINCOSTIV ¼ exp 8:4604ð Þ • bф ¼ 1:0792ð Þ
¼ 5097:99
dlnADMINCOSTSC ¼ 7:1499−3:2026 1ð Þ−5:2737 0ð Þ
þ :428 17:33ð Þ þ :404 1ð Þ
− :2896 1ð Þ− :00106 17:332 
− :3173 17:33ð Þ 1ð Þ
dADMINCOSTSC ¼ exp 5:6618ð Þ • bф ¼ 1:3799ð Þ
¼ 396:94
where 1.0792 and 1.3799 are the subgroup-specific
smearing factors for intravenous and subcutaneous
products respectively. Assuming the same price per
given dose, this represents a healthcare delivery cost
saving of, at least, £4700 per patient per year.
These results are consistent with Samanta et al.’s [22]
report that a 100% switch of 200 patients in England
receiving intravenous trastuzumab to its subcutaneous
equivalent will generate time and resource cost savings
of £271,000 in the hospital setting; £1,200,000 in the com-
munity setting and £1,500,000 if patients self-administer
subcutaneous trastuzumab at home. The savings arise
mainly from reduction in pharmacy technicians’ time and
£
£
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being hospitalised to receive an intravenous infusion.
Our regression-based algorithm provides a conservative
estimate of £940,200 if 200 patients fully switch from
intravenous to self-administered subcutaneous trastuzu-
mab. Also De Cock et al. [23] report, from a multi-country,
multi-centre time and motion study that resources
expended in administering intravenous trastuzumab is
mainly in the form of reconstitution in the pharmacy and
in “infusion initiation” (no changes in number of patients
visits, blood sampling and physician consultation were
expected from the switch to subcutaneous trastuzumab).
Our results are consistent with this finding as we found
that the ratio PAc/Pc is greater than or equal to one in only
9% of 1000 simulations for trastuzumab.
Discussion
The essence of our administration-cost algorithm is best
appreciated when one considers the argument by de la
Horie [24] that the reason why biologics are “so expen-
sive” is because of complex and costly manufacturing, and
the need for frequent administration of high doses to be
effective. This suggests that healthcare delivery costs could
be reduced by manufacturing process innovations that
reduce the cost of making biologic drugs as well as refor-
mulation steps that reduce the frequency of dosing. Our
results suggest that this is possible but then the curvilinear
relationship between ADMINCOST and DOSFREQ means
it is also possible for some biologic drugs (given their
peculiar biophysical characteristics and pharmacokinetic
profiles) to have lower administration costs even with a
higher annual dosing frequency (relative to some other
biologic drug). However, for our product sample, an
increase in DOSFREQ in most cases will be associated
with an increase in ADMINCOST albeit at a dimin-
ishing marginal rate. But we know that the variables
SUBCUTANEOUS and INTRAMUSUCLAR are associ-
ated with lower administration costs even when DOSFREQ
remains unchanged. We could therefore say the key de-
cision factor is with regards to formulating a product for
subcutaneous or intramuscular administration relative to
intravenous delivery.
In line with the argument by Eisenstein [25], a one-
size-fits-all approach of formulating biologics for intra-
venous delivery needs to be reconsidered. This, however,
should not be taken to mean that all biologics should be
manufactured for subcutaneous or intramuscular admin-
istration. Intravenous administration has other attributes
that make it the most appropriate route for administering
a drug. This includes the benefit of immediate injection of
active drug moieties into the systemic circulation – some-
thing that is desired when an immediate treatment or
clinical response is needed. Intravenous delivery is also
appropriate for products with narrow therapeutic indicesas there is less fluctuations of drug levels in blood plasma.
Generally speaking, drugs that need ‘informed’ dosage
adjustments (based on accurate measurements of some
physiological or biochemical metric) in order to ensure
the products deliver positive health benefits (net of safety
concerns and risks) are best administered intravenously.
Intravenous delivery is also appropriate when a drug
cannot be absorbed from the gastrointestinal tract or
when a drug cannot be injected into the muscle or other
body tissues [26]. Putting aside these clinical reasons,
there are manufacturing challenges (issues of techno-
logical feasibility) that need to be addressed before the
potential efficiency (cost) savings can be realized.
Biologics can be difficult to formulate for subcutane-
ous or intramuscular delivery as this typically involves
injection of small volumes of highly concentrated drug
solutions through needles with narrow apertures (needles
used for subcutaneous often have an aperture of 0.5 inches
whilst needles with 1-2 inch gauges are used for intramus-
cular delivery). The problem is amplified for biologics that
need to be given in high doses and/or have limited solubil-
ity. Subsequently, attempts to formulate biologic drugs
with fragile molecular structures in high concentrations
and small volumes could lead to protein aggregation,
undesirable viscosity properties and generally ‘unstable’
drugs that do not retain their biological or biophysical
properties. A biologic drug that works well when given in
high volumes (because of solubility problems for example)
as an intravenous infusion may lose its clinical efficacy or
product quality when formulated for subcutaneous or
intramuscular delivery in small volumes [27,25]. What is
more if the small volumes of subcutaneous or intramuscu-
lar biologics needed to be injected results in an in-
crease in DOSFREQ for a biologic product, the net
impact will be determined mainly by the opposing effects
of SUBCUTANEOUS or INTRAMUSCULAR and
DOSFREQ. Note that this effect of DOSFREQ from fre-
quent subcutaneous or intramuscular injections of small
volumes is irrespective of whether the biologic product in
question has a longer half-life that, all things being equal,
should lead to a lower DOSFREQ.
Another reason why subcutaneous or intramuscular
formulation might be associated with an increase in
DOSFREQ or higher doses is that biologics given intra-
muscular or subcutaneously will have go through layers
of skin or muscle tissues, and in the process they may be
rendered ineffective or fail to reach the desired target
sites. That is, if X doses of a drug are needed for the
desired clinical outcome, some allowance (W) must be
made for the lost or trapped drug doses by administering
X +W doses of the drug. In fact, this problem is the rea-
son behind the conduct of clinical trials on reformulated
trastuzumab, rituximab and immunoglobulin G with
recombinant hyaluronidase to enhance drug absorption
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net effect of SUBCUTANEOUS or INTRAMUSUCLAR
and DOSFREQ is a reduction in administration costs, this
cost saving might be offset by the fact for a given fixed
price per dose, a higher DOSFREQ increases the acquisi-
tion costs for that biologic drug. Again, depending on the
trade-off between acquisition and administration costs,
the overall impact might not be a reduction in disease
management or total healthcare delivery costs. Likewise,
for the same DOSFREQ, if it costs more to make the
reformulated product then to maintain the same price-
cost margin, this will lead to a higher product price per
dose assuming price demand elasticity remains the same.
That said, our regression-based algorithm in these situa-
tions should help manufacturers quantify the net impact
of their (re) formulation choices on drug administration
costs. This, together with considerations of expected prod-
uct prices, will allow them to generate credible estimates
of the total healthcare delivery costs of their products
and the likelihood that these products will find favourable
recommendations from healthcare payers or providers.
It might be argued that our regression-based algorithm
is tied to the product sample selected; that different
results may be obtained if a different biologic drug sam-
ple is used, perhaps one that has a lot more products
that are administered intramuscularly. Besides the obser-
vation that biologics are rarely formulated for intramus-
cular administration, that argument is not specific to our
case: it is applicable to almost algorithm that has been
developed for one purpose or the other. Our regression-
based algorithm may not yield the desired predictions in
all situations. That aside, there are non-monetary aspects
of drug administration that we haven’t considered here;
for example, needle phobia and patient discomfort; incon-
venience, disruption of daily activities (from more frequent
drug dosing) and non-compliance issues that might
negatively affect patients’ health. We will argue that it is
even possible to have an expanded algorithm that when
used to predict the impact on drug formulation choice
on healthcare delivery considers both the monetary and
non-monetary aspects of drug administration. We sug-
gest that further research is undertaken to evaluate, if
possible in monetary terms, the non-monetary attributes
of drug administration.
Even then an unanswered question is whether bio-
pharmaceutical manufacturers are faced with adequate
incentives to consider alternative drug delivery systems
or alter their formulation choices as early as possible.
From the perspective of the rational or responsible pri-
vate biopharmaceutical manufacturer, developing alter-
native drug delivery systems is worth the time, effort
and money if the net present value of that decision is
positive (see Chess [28]). That is to say, the discounted
present value of the stream of incremental quasi-rents(i.e., additional revenue minus the cost of goods) that a
reformulated biologic product or an alternative drug
delivery system is expected to bring should exceed the
discounted present value of the incremental costs of
developing the alternative drug delivery system or re-
formulating a product. Within the UK NHS the use
of CEA (HTA) and current efforts to implement
value-based pricing (partly based on estimated cost-
effectiveness) could and should provide some incentive
for manufacturers to consider the relationship between
formulation choices and healthcare delivery costs as
early as possible in product development but here we
cannot say anything about whether this, on its own,
will get manufacturers to change their tact. We believe
this is also worth considering in future research.
Conclusions
In this paper, we have evaluated variations in the magni-
tude of administration costs of biologic drugs, taking
care to ensure consistent inclusion of all relevant cost
resources. From this, we developed a regression-based
algorithm with which manufacturers could possibly pre-
dict, during process development, how their choices on
manufacturing and formulation may impact on the
healthcare delivery costs of their products. Our results
confirm the general notion that the administration costs
of intravenous products is higher than that or products
administered subcutaneously or intramuscularly. We found
that formulating a biologic drug for subcutaneous or intra-
muscular delivery relative to intravenous delivery is associ-
ated with lower administration costs that, holding all else
equal, should lead to lower total healthcare delivery costs.
Increasing the frequency of drug dosing generally will lead
to an increase in administration costs but it is possible that
this might not always be the case.
There are, however, clinical considerations and manu-
facturing challenges that might militate against the
potential efficiency savings in administration costs from
reformulating biologic products or making use of alterna-
tive drug delivery systems. But where and when issues of
technological feasibility can be dealt with, (bio)pharma-
ceutical manufacturers could use our algorithm to quantify
the net impact on drug administration costs, which to-
gether with considerations on the impact on acquisition
costs will allow them to generate credible estimates of the
total healthcare delivery costs for their products and the
likelihood that these products will find favourable recom-
mendations from healthcare payers.
Endnotes
aOur choice of 1000 simulations is not arbitrary. A
simulation convergence test, which is not reported in
the paper, suggests a virtually flat administration-cost
curve with the number of simulation trials ranging from
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lation 200 times.
bIn contrast to Basu & Rathouz [16], we found that the
PGLM/EEE with a power variance function failed to con-
verge. Misspecification tests for the PGLM/EEE (QV) sug-
gested a good fit with the data: Pearson correlation
between the raw-scale residuals and predicted values was
not significantly different from zero, and there was no
statistically-significant evidence of systematic patterns in
the residuals plotted against predicted values.
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